What is Ironwood Pharmaceuticals, Inc.'s earnings per share (EPS)?

Ironwood Pharmaceuticals, Inc. (IRWD) reported diluted earnings per share of $0.15 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ironwood Pharmaceuticals, Inc. (IRWD) Financials

IRWD

FY2025 annual

Revenue $296.2M -15.7% YoY

Net Income $24.0M +2629.2% YoY

EPS (Diluted) $0.15 YoY not available

Free Cash Flow $127.0M +22.8% YoY

Market Cap $589.9M as of Oct 22, 2026

Price / Sales 1.5x on $389.3M revenue, trailing 12 months to June 30, 2026

Price / Earnings 4.5x on $129.9M net income, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IRWD SEC filings page.

Ironwood Pharmaceuticals, Inc. (IRWD) reported $296.2M in revenue for fiscal year 2025, down 15.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IRWD FY2025 2026-10-03

Revenue is shrinking, yet lower operating costs and low reinvestment are preserving cash generation.

Revenue fell 15.7% in FY2025 even as operating margin widened to 33.3%. That combination points to a leaner cost structure or more favorable mix, rather than growth-driven leverage.

Operating cash flow rose from $103.5M in FY2024 to $127.0M in FY2025. Cash generation materially exceeded accounting profit in FY2025, and free cash flow nearly matched it, indicating little cash was absorbed by reinvestment.

FY2025 liabilities were $658.7M against total assets of $396.9M. That leaves negative equity and a current ratio of 1.1x, a much narrower short-term cushion than FY2024's 4.7x.

Financial Health Signals

Financial Health Score 34/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Ironwood Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Ironwood Pharmaceuticals, Inc. has an operating margin of 33.3%, meaning the company retains $33 of operating profit per $100 of revenue. Among its peers this margin ranks in the lower range, for a profitability score of 10/100. This is up from 26.5% the prior year.

Growth

Ironwood Pharmaceuticals, Inc.'s revenue declined 15.7% year-over-year, from $351.4M to $296.2M. This contraction results in a growth score of 5/100.

Leverage

Liquidity

Ironwood Pharmaceuticals, Inc.'s current ratio of 1.13 is below the typical benchmark, resulting in a score of 26/100. However, the company holds substantial cash reserves (89% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Cash Flow

Ironwood Pharmaceuticals, Inc. converts 42.9% of revenue into free cash flow ($127.0M). This strong cash generation earns a score of 97/100.

Returns

Altman Z-Score Distress

-3.70

Ironwood Pharmaceuticals, Inc. scores -3.70, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.7B against total assets of $396.9M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/7

Ironwood Pharmaceuticals, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality Cash-Backed

5.29x

For every $1 of reported earnings, Ironwood Pharmaceuticals, Inc. generates $5.29 in operating cash flow ($127.0M OCF vs $24.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

3.01x

Ironwood Pharmaceuticals, Inc. earns $3.01 in operating income for every $1 of interest expense ($98.5M vs $32.7M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$113.0M

YoY+32.6%

QoQ+6.1%

5Y CAGR+1.7%

10Y CAGR+7.6%

Ironwood Pharmaceuticals, Inc. generated $113.0M in revenue in Q2 2026. This represents an increase of 32.6% from the same quarter a year earlier. Against the prior quarter it is up 6.1%.

EBITDA

$79.8M

YoY+74.2%

QoQ+9.2%

Ironwood Pharmaceuticals, Inc.'s EBITDA was $79.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 74.2% from the same quarter a year earlier. Against the prior quarter it is up 9.2%.

Net Income

$51.3M

YoY+117.3%

QoQ+25.8%

5Y CAGR-33.4%

10Y CAGRn/m

Ironwood Pharmaceuticals, Inc. reported $51.3M in net income in Q2 2026. This represents an increase of 117.3% from the same quarter a year earlier. Against the prior quarter it is up 25.8%.

EPS (Diluted)

$0.31

YoY+121.4%

QoQ+29.2%

Ironwood Pharmaceuticals, Inc. earned $0.31 per diluted share (EPS) in Q2 2026. This represents an increase of 121.4% from the same quarter a year earlier. Against the prior quarter it is up 29.2%.

Cash & Balance Sheet

Cash & Debt

$79.1M

YoY-14.8%

QoQ-64.1%

5Y CAGR-30.6%

10Y CAGR-11.8%

Ironwood Pharmaceuticals, Inc. held $79.1M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding

165M

YoY+1.7%

QoQ+0.4%

Ironwood Pharmaceuticals, Inc. had 165M shares outstanding in Q2 2026. This represents an increase of 1.7% from the same quarter a year earlier. Against the prior quarter it is up 0.4%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Operating Margin

70.2%

YoY+17.0pp

QoQ+2.0pp

Ironwood Pharmaceuticals, Inc.'s operating margin was 70.2% in Q2 2026, reflecting core business profitability. This is up 17.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.0 percentage points.

Net Margin

45.4%

YoY+17.7pp

QoQ+7.1pp

10Y change+85.3pp

Ironwood Pharmaceuticals, Inc.'s net profit margin was 45.4% in Q2 2026, showing the share of revenue converted to profit. This is up 17.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.1 percentage points.

Gross Margin

Not reported for Q2 2026.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$22.4M

YoY-4.1%

QoQ+2.2%

Ironwood Pharmaceuticals, Inc. invested $22.4M in research and development in Q2 2026. This represents a decrease of 4.1% from the same quarter a year earlier. Against the prior quarter it is up 2.2%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

IRWD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IRWD quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$389.3M	$296.2M-15.7%	$351.4M-20.6%	$442.7M+7.8%	$410.6M-0.8%	$413.8M+6.2%	$389.5M-9.1%	$428.4M+23.6%	$346.6M+16.2%	$298.3M+8.9%	$274.0M+83.2%	$149.6M+95.7%	$76.4M+234.1%	$22.9M-84.8%	$150.2M+128.1%	$65.9M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$3.1M-86.9%	$23.9M-27.1%	$32.8M+71.5%	$19.1M+922.3%	$1.9M+15466.7%	$12K-99.8%	$5.3M-26.5%	$7.2M+646.4%	$965K	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	$386.4M-4.5%	$404.5M+28.9%	$313.9M+12.4%	$279.2M+2.6%	$272.1M+81.9%	$149.5M+110.2%	$71.1M+353.8%	$15.7M-89.5%	$149.3M	N/A
R&D Expenses	N/A	$95.1M-14.6%	$111.4M-4.0%	$116.1M+162.3%	$44.3M-37.1%	$70.4M-20.1%	$88.1M-23.5%	$115.0M+13.8%	$101.1M+14.7%	$88.1M-36.8%	$139.5M+28.3%	$108.7M+6.7%	$101.9M-0.5%	$102.4M-9.8%	$113.5M+31.8%	$86.1M
SG&A Expenses	N/A	$82.3M-43.0%	$144.3M-8.9%	$158.3M+36.5%	$116.0M+4.4%	$111.1M-20.6%	$140.0M-18.8%	$172.4M-21.5%	$219.7M-5.0%	$231.2M+33.4%	$173.3M+38.4%	$125.2M+5.8%	$118.3M-4.0%	$123.2M+33.2%	$92.5M+101.5%	$45.9M
Operating Income	N/A	$98.5M+5.8%	$93.1Mn/m	-$945.4M-477.7%	$250.3M+7.8%	$232.3M+62.5%	$142.9M+19.0%	$120.1Mn/m	-$150.7Mn/m	-$15.4Mn/m	-$51.9Mn/m	-$102.1Mn/m	-$169.4Mn/m	-$252.0Mn/m	-$72.8Mn/m	-$66.1M
EBITDA	N/A	$99.6M+5.6%	$94.3Mn/m	-$944.2M-475.1%	$251.7M+7.7%	$233.8M+60.9%	$145.2M+15.5%	$125.7Mn/m	-$146.8Mn/m	-$9.0Mn/m	-$41.6Mn/m	-$90.5Mn/m	-$157.0Mn/m	-$240.3Mn/m	-$61.4Mn/m	-$56.1M
Interest Expense	N/A	$32.7M-0.9%	$33.0M+52.7%	$21.6M+184.7%	$7.6M-75.6%	$31.1M+5.7%	$29.5M-19.5%	$36.6M-3.0%	$37.7M+3.7%	$36.4M-7.1%	$39.2M+25.9%	$31.1M+46.9%	$21.2M+0.8%	$21.0M+35496.6%	$59K-6.3%	$63K
Income Tax	N/A	$46.0M-28.5%	$64.3M-23.0%	$83.5M+7.9%	$77.4Mn/m	-$327.8M-12308.2%	$2.7Mn/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0	N/A	N/A	$3K
Net Income	$129.9M	$24.0M+2629.2%	$880Kn/m	-$1.0B-672.5%	$175.1M-66.9%	$528.4M+397.7%	$106.2M+393.7%	$21.5Mn/m	-$282.4Mn/m	-$116.9Mn/m	-$81.7Mn/m	-$142.7Mn/m	-$189.6Mn/m	-$272.8Mn/m	-$72.6Mn/m	-$64.9M
EPS (Basic)	N/A	$0.15	$0.01	-$6.45-670.8%	$1.13-65.3%	$3.26+386.6%	$0.67+378.6%	$0.14n/m	-$1.85n/m	-$0.78n/m	-$0.56n/m	-$1.00n/m	-$1.39n/m	-$2.35n/m	-$0.68n/m	-$0.65
EPS (Diluted)	$0.77	$0.15	$0.01	-$6.45-771.9%	$0.96-70.1%	$3.21+386.4%	$0.66+371.4%	$0.14n/m	-$1.85n/m	-$0.78n/m	-$0.56n/m	-$1.00n/m	-$1.39n/m	-$2.35n/m	-$0.68n/m	-$0.65
Diluted Shares (Avg)	N/A	163M	160M	155M-16.6%	186M+13.3%	164M+2.3%	161M+3.0%	156M+2.2%	153M	N/A	N/A	N/A	N/A	N/A	N/A	100M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-K	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-K
Revenue	$113.0M+32.6%	$106.5M+158.9%	$47.7M-47.3%	$122.1M+33.3%	$85.2M-9.7%	$41.1M-45.1%	$90.5M-23.0%	$91.6M-19.5%
R&D Expenses	$22.4M-4.1%	$21.9M-20.0%	N/A	$22.5M-24.7%	$23.4M-23.1%	$27.4M+6.3%	N/A	$29.8M-9.6%
SG&A Expenses	$11.3M-32.6%	$12.0M-50.4%	N/A	$21.9M-39.3%	$16.8M-54.6%	$24.3M-35.5%	N/A	$36.1M+0.2%
Operating Income	$79.3M+75.0%	$72.6Mn/m	N/A	$75.5M+194.4%	$45.3M+81.5%	-$29.1M-364.1%	N/A	$25.6M-35.9%
EBITDA	$79.8M+74.2%	$73.0Mn/m	N/A	$76.0M+190.6%	$45.8M+79.7%	-$28.6M-348.2%	N/A	$26.1M-35.5%
Interest Expense	$7.2M-13.8%	$9.1M+13.3%	N/A	$8.4M-10.5%	$8.4M+11.9%	$8.1M+11.6%	N/A	$9.4M-4.3%
Income Tax	$22.4M+57.8%	$24.4M+2090.2%	N/A	$27.9M+103.6%	$14.2M-27.9%	$1.1M-87.8%	N/A	$13.7M-23.7%
Net Income	$51.3M+117.3%	$40.8Mn/m	-$2.3M-200.9%	$40.1M+999.3%	$23.6Mn/m	-$37.4Mn/m	$2.3Mn/m	$3.6M-76.2%
EPS (Basic)	$0.31+106.7%	$0.25n/m	-$0.01-200.0%	$0.25+1150.0%	$0.15	-$0.23n/m	$0.01	$0.02-80.0%
EPS (Diluted)	$0.31+121.4%	$0.24n/m	-$0.01-200.0%	$0.23+1050.0%	$0.14	-$0.23n/m	$0.01	$0.02-77.8%
Diluted Shares (Avg)	167M-5.5%	167M+3.6%	N/A	178M+10.9%	177M	161M+2.1%	N/A	160M-14.3%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

IRWD Balance Sheet

IRWD quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$396.9M+13.1%	$350.9M-25.5%	$471.1M-57.2%	$1.1B-2.3%	$1.1B+101.5%	$559.2M+38.9%	$402.7M+21.3%	$332.1M-45.2%	$605.7M-14.7%	$709.8M+14.6%	$619.1M+88.0%	$329.3M+18.1%	$279.0M+21.3%	$229.9M+10.0%	$209.0M
Current Assets	$274.2M+50.3%	$182.4M-21.8%	$233.3M-70.1%	$780.6M+4.8%	$745.2M+50.3%	$495.8M+61.6%	$306.9M+15.2%	$266.4M-14.5%	$311.6M-18.0%	$380.2M-24.0%	$500.2M+73.5%	$288.3M+25.8%	$229.1M+24.2%	$184.4M+10.1%	$167.6M
Cash & Equivalents	$215.5M+143.3%	$88.6M-3.9%	$92.2M-86.0%	$656.2M+5.8%	$620.1M+71.0%	$362.6M+104.8%	$177.0M+2.2%	$173.2M+37.7%	$125.7M+132.8%	$54.0M-79.3%	$261.3M+251.7%	$74.3M-1.6%	$75.5M-44.8%	$136.7M+56.6%	$87.3M
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0-100.0%	$95.7M-61.9%	$251.2M+41.0%	$178.1M+2.3%	$174.0M+42.5%	$122.1M+287.3%	$31.5M-58.9%	$76.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	$648K	N/A	$735K-32.0%	$1.1M	N/A	$5.0M-77.4%	$22.1M+230.6%	$6.7M	N/A
Accounts Receivable	$46.7M-42.9%	$81.9M-36.6%	$129.1M+11.8%	$115.5M+1.2%	$114.0M-6.8%	$122.4M+984.8%	$11.3M-46.3%	$21.0M+558.0%	$3.2M+241.9%	$933K-67.6%	$2.9M+28740.0%	$10K-98.1%	$513K+12.3%	$457K+517.6%	$74K
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$785K0.0%	$785K0.0%	$785K0.0%	$785K	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$658.7M+1.0%	$652.2M-20.2%	$817.4M+82.4%	$448.1M-14.0%	$521.0M+4.9%	$496.6M+0.1%	$496.0M-6.1%	$528.4M-11.3%	$595.8M-7.4%	$643.1M+22.7%	$524.0M+117.6%	$240.8M0.0%	$240.7M+180.4%	$85.9M-13.4%	$99.1M
Current Liabilities	$242.2M+523.5%	$38.8M-85.9%	$276.1M+981.7%	$25.5M-84.2%	$161.7M+402.6%	$32.2M-21.4%	$40.9M-65.8%	$119.5M+81.0%	$66.0M-27.5%	$91.1M+19.2%	$76.5M+26.3%	$60.5M+47.5%	$41.0M-25.3%	$54.9M-15.7%	$65.1M
Non-Current Liabilities	$416.5M-32.1%	$613.4M+13.3%	$541.3M+28.1%	$422.6M+17.6%	$359.3M-22.6%	$464.4M+2.1%	$455.1M+11.3%	$408.9M-22.8%	$529.8M-4.0%	$552.0M+23.3%	$447.5M+148.3%	$180.2M-9.7%	$199.7M+545.9%	$30.9M-9.0%	$34.0M
Long-Term Debt	N/A	$199.0M-50.0%	$397.9M+0.4%	$396.3M-12.8%	$454.2M+5.6%	$430.3M+5.5%	$408.0M+53.6%	$265.6M+6.6%	$249.2M	N/A	$220.6M	N/A	N/A	N/A	N/A
Total Equity	-$261.8Mn/m	-$301.3Mn/m	-$346.3M-153.1%	$652.4M+7.7%	$605.9M+867.3%	$62.6Mn/m	-$93.3Mn/m	-$196.4M-2094.0%	$9.8M-85.2%	$66.7M-29.9%	$95.1M+7.4%	$88.6M+131.7%	$38.2M-73.5%	$144.1M+31.1%	$109.9M
Retained Earnings	-$1.7Bn/m	-$1.7Bn/m	-$1.7Bn/m	-$696.4Mn/m	-$937.6Mn/m	-$1.5Bn/m	-$1.6Bn/m	-$1.6Bn/m	-$1.3Bn/m	-$1.2Bn/m	-$1.1Bn/m	-$967.4Mn/m	-$777.8Mn/m	-$505.0Mn/m	-$432.4M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-K	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-K
Total Assets	$285.1M-16.9%	$434.6M+32.8%	$396.9M+13.1%	$396.1M+1.7%	$342.9M-13.3%	$327.2M-25.4%	$350.9M-25.5%	$389.5M-25.7%
Current Assets	$199.2M+3.9%	$332.3M+106.9%	$274.2M+50.3%	$273.8M+53.3%	$191.8M+7.6%	$160.6M-22.9%	$182.4M-21.8%	$178.6M-29.6%
Cash & Equivalents	$79.1M-14.8%	$220.5M+103.2%	$215.5M+143.3%	$140.4M+59.2%	$92.9M-12.0%	$108.5M-10.7%	$88.6M-3.9%	$88.2M-19.9%
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Accounts Receivable	$112.7M+30.8%	$105.8M+166.1%	$46.7M-42.9%	$120.4M+58.0%	$86.2M+48.3%	$39.8M-44.8%	$81.9M-36.6%	$76.2M-38.8%
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Total Liabilities	$447.0M-31.4%	$651.7M-1.4%	$658.7M+1.0%	$660.2M-5.8%	$651.1M-9.2%	$661.3M-14.0%	$652.2M-20.2%	$700.9M-17.3%
Current Liabilities	$32.9M-85.9%	$236.3M+391.3%	$242.2M+523.5%	$242.5M+391.1%	$232.5M+410.9%	$48.1M-80.9%	$38.8M-85.9%	$49.4M-82.4%
Non-Current Liabilities	$414.1M-1.1%	$415.4M-32.3%	$416.5M-32.1%	$417.7M-35.9%	$418.6M-37.7%	$613.2M+18.6%	$613.4M+13.3%	$651.5M+15.0%
Long-Term Debt	N/A	N/A	N/A	$199.5M+0.3%	$199.3M+0.3%	$199.2M-50.0%	$199.0M-50.0%	$198.8M-50.0%
Total Equity	-$161.8Mn/m	-$217.1Mn/m	-$261.8Mn/m	-$264.2Mn/m	-$308.2Mn/m	-$334.1Mn/m	-$301.3Mn/m	-$311.3Mn/m
Retained Earnings	-$1.6Bn/m	-$1.6Bn/m	-$1.7Bn/m	-$1.7Bn/m	-$1.7Bn/m	-$1.7Bn/m	-$1.7Bn/m	-$1.7Bn/m

Not reported in any period shown, so not listed: Inventory, Goodwill.

IRWD Cash Flow Statement

IRWD quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$185.6M	$127.0M+22.7%	$103.5M-43.5%	$183.4M-33.0%	$273.8M+4.5%	$261.9M+55.1%	$168.8M+1474.2%	$10.7Mn/m	-$70.9Mn/m	-$100.8Mn/m	-$25.9Mn/m	-$106.9Mn/m	-$155.6Mn/m	-$273.4Mn/m	-$69.6Mn/m	-$75.2M
Depreciation & Amortization	N/A	$1.1M-8.3%	$1.2M0.0%	$1.2M-14.3%	$1.4M-6.7%	$1.5M-34.8%	$2.3M-58.9%	$5.6M+43.6%	$3.9M-39.1%	$6.4M-37.7%	$10.3M-11.6%	$11.6M-5.7%	$12.3M+5.1%	$11.7M+3.6%	$11.3M+13.3%	$10.0M
Stock-Based Compensation	N/A	$17.3M-42.2%	$29.9M-6.7%	$32.0M+18.3%	$27.0M+21.4%	$22.3M-28.5%	$31.2M-0.3%	$31.3M-22.8%	$40.5M+31.1%	$30.9M+5.8%	$29.2M+14.7%	$25.5M-2.7%	$26.2M+32.0%	$19.8M+12.8%	$17.6M+49.8%	$11.7M
Capital Expenditures	N/A	$34K-76.1%	$142K-48.0%	$273K+100.7%	$136K-48.7%	$265K-85.6%	$1.8M-74.4%	$7.2M+1948.1%	$351K-87.5%	$2.8M-33.4%	$4.2M+3.9%	$4.0M+14.4%	$3.5M-63.1%	$9.6M-31.4%	$14.0M+44.4%	$9.7M
Free Cash Flow	N/A	$127.0M+22.8%	$103.4M-43.5%	$183.2M-33.1%	$273.6M+4.6%	$261.6M+56.7%	$167.0M+4622.7%	$3.5Mn/m	-$71.2Mn/m	-$103.6Mn/m	-$30.1Mn/m	-$111.0Mn/m	-$159.1Mn/m	-$282.9Mn/m	-$83.6Mn/m	-$84.9M
Investing Cash Flow	N/A	-$34Kn/m	-$142Kn/m	-$1.0Bn/m	-$136Kn/m	-$265Kn/m	-$1.8Mn/m	-$11.1M-112.5%	$88.9M-41.3%	$151.5Mn/m	-$177.7Mn/m	-$9.2Mn/m	-$56.6Mn/m	-$101.4M-437.2%	$30.1M-73.9%	$115.1M
Financing Cash Flow	N/A	$216Kn/m	-$107.0M-138.6%	$277.2Mn/m	-$237.6Mn/m	-$4.5M-124.5%	$18.5Mn/m	-$1.2M-103.9%	$30.1M+51.6%	$19.8Mn/m	-$4.2M-101.4%	$303.1M+43.7%	$210.9M-32.7%	$313.6M+252.4%	$89.0M+2739.9%	$3.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$126.4M+423.8%	$24.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-K	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-K
Operating Cash Flow	$58.3Mn/m	$5.1M-74.3%	$74.6M+390.2%	$47.6M+381.4%	-$15.1M-145.0%	$20.0M-55.6%	$15.2M-57.5%	$9.9M-69.5%
Depreciation & Amortization	$457K-2.1%	$443K-7.5%	N/A	$475K-6.3%	$467K-7.7%	$479K-6.6%	N/A	$507K0.0%
Stock-Based Compensation	$3.2M-28.5%	$3.7M-31.0%	N/A	$3.6M-56.6%	$4.5M-47.2%	$5.3M-36.9%	N/A	$8.3M+5.4%
Capital Expenditures	N/A	N/A	-$1Kn/m	$2K-87.5%	$2K-96.6%	$31K-54.4%	$0-100.0%	$16K-67.3%
Free Cash Flow	N/A	N/A	$74.6M+390.2%	$47.6M+382.1%	-$15.1M-145.1%	$19.9M-55.6%	$15.2M-57.3%	$9.9M-69.5%
Investing Cash Flow	N/A	N/A	$1Kn/m	-$2Kn/m	-$2Kn/m	-$31Kn/m	$0n/m	-$16Kn/m
Financing Cash Flow	N/A	N/A	$122Kn/m	$0n/m	$88Kn/m	$6Kn/m	-$14.9Mn/m	-$27.2Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

IRWD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IRWD quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	99.2%+4.8pp	94.4%+3.9pp	90.5%-3.1pp	93.6%-5.7pp	99.3%-0.7pp	100.0%+6.9pp	93.1%+24.6pp	68.5%-30.8pp	99.4%	N/A
Operating Margin	33.3%+6.8pp	26.5%	-213.5%	61.0%+4.8pp	56.1%+19.4pp	36.7%+8.7pp	28.0%+71.5pp	-43.5%-38.3pp	-5.1%+13.8pp	-18.9%+49.3pp	-68.3%	-221.6%	-1101.4%	-48.4%	-100.4%
Net Margin	8.1%+7.9pp	0.3%	-226.4%	42.6%	127.7%	27.3%+22.2pp	5.0%+86.5pp	-81.5%-42.3pp	-39.2%-9.4pp	-29.8%+65.6pp	-95.4%	-248.1%	-1192.3%	-48.3%+50.1pp	-98.5%
Return on Equity	N/A	N/A	N/A	26.8%-60.4pp	87.2%-82.3pp	169.5%	N/A	N/A	-1187.4%-1064.9pp	-122.5%+27.5pp	-150.0%+64.2pp	-214.1%+499.6pp	-713.7%-663.3pp	-50.4%+8.6pp	-59.0%
Return on Assets	6.0%+5.8pp	0.3%+213.0pp	-212.8%-228.7pp	15.9%-31.0pp	46.9%+27.9pp	19.0%+13.7pp	5.3%+90.4pp	-85.0%-65.7pp	-19.3%-7.8pp	-11.5%+11.5pp	-23.0%+34.5pp	-57.6%+40.2pp	-97.8%-66.2pp	-31.6%-0.6pp	-31.0%
Current Ratio	1.13-3.6x	4.69+3.8x	0.84-29.7x	30.58+26.0x	4.61-10.8x	15.41+7.9x	7.50+5.3x	2.23-2.5x	4.72+0.5x	4.17-2.4x	6.54+1.8x	4.76-0.8x	5.58+2.2x	3.36+0.8x	2.57
Debt-to-Equity	N/A	N/A	N/A	0.61-0.1x	0.75-6.1x	6.87	N/A	N/A	25.30	N/A	2.32	N/A	N/A	N/A	N/A
Liabilities-to-Equity	N/A	N/A	N/A	0.69-0.2x	0.86-7.1x	7.93	N/A	N/A	60.50+50.9x	9.64+4.1x	5.51+2.8x	2.72-3.6x	6.30+5.7x	0.60-0.3x	0.90
Asset Turnover	0.75-0.3x	1.00+0.1x	0.94+0.6x	0.370.0x	0.37-0.3x	0.70-0.4x	1.060.0x	1.04+0.6x	0.49+0.1x	0.39+0.1x	0.240.0x	0.23+0.2x	0.08-0.6x	0.65+0.3x	0.32
FCF Margin	42.9%+13.5pp	29.4%-11.9pp	41.4%-25.3pp	66.6%+3.4pp	63.2%+20.4pp	42.9%+42.0pp	0.8%+21.4pp	-20.5%+14.2pp	-34.7%-23.7pp	-11.0%+63.2pp	-74.2%	-208.2%	-1236.6%	-55.6%	-128.9%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-K	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-K
Operating Margin	70.2%+17.0pp	68.1%+138.9pp	N/A	61.8%+33.8pp	53.2%+26.7pp	-70.8%-85.5pp	N/A	28.0%-7.2pp
Net Margin	45.4%+17.7pp	38.3%+129.1pp	-4.8%-7.3pp	32.8%+28.9pp	27.7%+28.6pp	-90.9%-85.3pp	2.5%+3.4pp	4.0%-9.5pp
Return on Assets	18.0%+11.1pp	9.4%+20.8pp	-0.6%-1.2pp	10.1%+9.2pp	6.9%+7.1pp	-11.4%-10.5pp	0.6%+0.9pp	0.9%-2.0pp
Current Ratio	6.06+5.2x	1.41-1.9x	1.13-3.6x	1.13-2.5x	0.82-3.1x	3.34+2.5x	4.69+3.8x	3.62+2.7x
Asset Turnover	0.40+0.1x	0.25+0.1x	0.12-0.1x	0.31+0.1x	0.250.0x	0.130.0x	0.260.0x	0.240.0x
FCF Margin	N/A	N/A	156.3%	39.0%+28.2pp	-17.7%-53.1pp	48.4%-11.6pp	16.8%-13.5pp	10.8%-17.7pp

Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: FCF Margin.

Note: Shareholder equity is negative (-$261.8M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Ironwood Pharmaceuticals, Inc. IRWD	FY2025	$296.2M	$24.0M	8.1%	$589.9M	34/100
China SXT Pharmaceuticals, Inc. SXTC	FY2026	$1.1M	-$6.2M	N/A	$96K	51/100
Journey Medical Corporation DERM	FY2025	$61.9M	-$11.4M	-18.5%	$135.5M	32/100
BioAge Labs, Inc. BIOA	FY2025	$9.0M	-$80.6M	N/A	$252.9M	55/100
Alpha Teknova, Inc. TKNO	FY2025	$40.5M	-$17.3M	-42.6%	$314.1M	49/100

Where Ironwood Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

What is Ironwood Pharmaceuticals, Inc.'s annual revenue?

Ironwood Pharmaceuticals, Inc. (IRWD) reported $296.2M in total revenue for fiscal year 2025. This represents a -15.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ironwood Pharmaceuticals, Inc.'s revenue growing?

Ironwood Pharmaceuticals, Inc. (IRWD) revenue declined by 15.7% year-over-year, from $351.4M to $296.2M in fiscal year 2025.

Is Ironwood Pharmaceuticals, Inc. profitable?

Yes, Ironwood Pharmaceuticals, Inc. (IRWD) reported a net income of $24.0M in fiscal year 2025, with a net profit margin of 8.1%.

What is Ironwood Pharmaceuticals, Inc.'s EBITDA?

Ironwood Pharmaceuticals, Inc. (IRWD) had EBITDA of $99.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Ironwood Pharmaceuticals, Inc.'s operating margin?

Ironwood Pharmaceuticals, Inc. (IRWD) had an operating margin of 33.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Ironwood Pharmaceuticals, Inc.'s net profit margin?

Ironwood Pharmaceuticals, Inc. (IRWD) had a net profit margin of 8.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Ironwood Pharmaceuticals, Inc.'s free cash flow?

Ironwood Pharmaceuticals, Inc. (IRWD) generated $127.0M in free cash flow during fiscal year 2025. This represents a 22.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Ironwood Pharmaceuticals, Inc.'s operating cash flow?

Ironwood Pharmaceuticals, Inc. (IRWD) generated $127.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Ironwood Pharmaceuticals, Inc.'s total assets?

Ironwood Pharmaceuticals, Inc. (IRWD) had $396.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Ironwood Pharmaceuticals, Inc.'s capital expenditures?

Ironwood Pharmaceuticals, Inc. (IRWD) invested $34K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Ironwood Pharmaceuticals, Inc. spend on research and development?

Ironwood Pharmaceuticals, Inc. (IRWD) invested $95.1M in research and development during fiscal year 2025.

How many shares does Ironwood Pharmaceuticals, Inc. have outstanding?

Ironwood Pharmaceuticals, Inc. (IRWD) had 163M shares outstanding as of fiscal year 2025.

What is Ironwood Pharmaceuticals, Inc.'s current ratio?

Ironwood Pharmaceuticals, Inc. (IRWD) had a current ratio of 1.13 as of fiscal year 2025, which is considered adequate.

What is Ironwood Pharmaceuticals, Inc.'s return on assets (ROA)?

Ironwood Pharmaceuticals, Inc. (IRWD) had a return on assets of 6.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Ironwood Pharmaceuticals, Inc.'s P/E ratio?

Ironwood Pharmaceuticals, Inc. (IRWD) trades at 4.5x earnings, its market capitalization divided by $129.9M net income, trailing 12 months to June 30, 2026. The market capitalization is $589.9M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Ironwood Pharmaceuticals, Inc.'s price-to-sales ratio?

Ironwood Pharmaceuticals, Inc. (IRWD) trades at 1.5x sales, its market capitalization divided by $389.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $589.9M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is Ironwood Pharmaceuticals, Inc.'s debt-to-equity ratio negative or not reported?

Ironwood Pharmaceuticals, Inc. (IRWD) has negative shareholder equity of -$261.8M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Ironwood Pharmaceuticals, Inc.'s Altman Z-Score?

Ironwood Pharmaceuticals, Inc. (IRWD) has an Altman Z-Score of -3.70, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Ironwood Pharmaceuticals, Inc.'s Piotroski F-Score?

Ironwood Pharmaceuticals, Inc. (IRWD) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Ironwood Pharmaceuticals, Inc.'s earnings high quality?

Ironwood Pharmaceuticals, Inc. (IRWD) has an earnings quality ratio of 5.29x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Ironwood Pharmaceuticals, Inc. cover its interest payments?

Ironwood Pharmaceuticals, Inc. (IRWD) has an interest coverage ratio of 3.01x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Ironwood Pharmaceuticals, Inc.?

Ironwood Pharmaceuticals, Inc. (IRWD) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.